Acute disseminated encephalomyelitis with severe neurological outcomes following virosomal seasonal influenza vaccine

• Published in: Human vaccines & immunotherapeutics Vol. 10; no. 7; pp. 1969 - 1973
• Main Authors: Alicino, Cristiano, Infante, Maria Teresa, Gandoglia, Ilaria, Miolo, Nadia, Mancardi, Gian Luigi, Zappettini, Simona, Capello, Elisabetta, Orsi, Andrea, Tamburini, Tiziano, Grandis, Marina
• Format: Journal Article
• Language: English
• Published: Landes Bioscience 01.05.2014
• Subjects: Case Report
• ISSN: 2164-5515; 2164-554X
• DOI: 10.4161/hv.28961

Acute disseminated encephalomyelitis (ADEM) is an inflammatory, usually monophasic, immune mediate, demyelinating disease of the central nervous system which involves the white matter. ADEM is more frequent in children and usually occurs after viral infections, but may follow vaccinations, bacterial infections, or may occur without previous events. Only 5% of cases of ADEM are preceded by vaccination within one month prior to symptoms onset. The diagnosis of ADEM requires both multifocal involvement and encephalopathy and specific demyelinating lesions of white matter. Overall prognosis of ADEM patients is often favorable, with full recovery reported in 23% to 100% of patients from pediatric cohorts, and more severe outcome in adult patients. We describe the first case of ADEM occurred few days after administration of virosomal seasonal influenza vaccine. The patient, a 59-year-old caucasic man with unremarkable past medical history presented at admission decreased alertness, 10 days after flu vaccination. During the 2 days following hospitalization, his clinical conditions deteriorated with drowsiness and fever until coma. The magnetic resonance imaging of the brain showed multiple and symmetrical white matter lesions in both cerebellar and cerebral hemispheres, suggesting demyelinating disease with inflammatory activity, compatible with ADEM. The patient was treated with high dose of steroids and intravenous immunoglobulin with relevant sequelae and severe neurological outcomes.